Dashboard
Manage Tickers

ALLO


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-keysight-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday
This Keysight Analyst Is No Longer Bullish...
10/10/2025 13:53:02

jp-morgan-downgrades-allogene-therapeutics-to-underweight
JP Morgan Downgrades Allogene Therapeutics...
10/10/2025 11:38:49

JP Morgan analyst Brian Cheng downgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Underweight.

allogene-therapeutics-q2-eps-023-beats-028-estimate
Allogene Therapeutics Q2 EPS $(0.23) Beats...
08/13/2025 20:38:42

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of...

Core News & Articles
Earnings Scheduled For August 13, 2025
08/13/2025 08:32:30

a-look-at-allogene-therapeuticss-upcoming-earnings-report
A Look at Allogene Therapeutics's Upcoming...
08/12/2025 18:02:55

jmp-securities-reiterates-market-perform-on-allogene-therapeuticsto-market-perform
JMP Securities Reiterates Market Perform o...
08/04/2025 14:28:24

JMP Securities analyst Reni Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) from Market Perform to Market Perform.

this-avalonbay-communities-analyst-is-no-longer-bullish-here-are-top-4-downgrades-for-monday
This AvalonBay Communities Analyst Is No L...
08/04/2025 11:47:31

jp-morgan-downgrades-allogene-therapeutics-to-neutral
JP Morgan Downgrades Allogene Therapeutics...
08/04/2025 10:00:46

JP Morgan analyst Brian Cheng downgrades Allogene Therapeutics (NASDAQ:ALLO) from Overweight to Neutral.

allogene-resets-clinical-course-after-patient-death-in-lymphoma-study
Allogene Resets Clinical Course After Pati...
08/01/2025 16:52:06

Allogene revised its LBCL trial after a fatal adverse event linked to ALLO-647, shifting to a standard FC regimen and updating ...

allogene-therapeutics-fc-plus-allo-647-arm-closed-early-due-to-grade-5-adverse-event-linked-to-allo-647-with-hepatic-failure-from-adenovirus-on-day-54
Allogene Therapeutics FC Plus ALLO-647 Arm...
08/01/2025 13:32:00

-SEC Filing

allogene-therapeutics-selects-selected-standard-fludarabine-and-cyclophosphamide-as-lymphodepletion-regimen-to-be-used-in-alpha3-study-evaluating-cemacabtagene-ansegedleucel-in-first-line-consolidation-for-large-b-cell-lymphoma
Allogene Therapeutics Selects Selected Sta...
08/01/2025 12:37:24

Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Comm...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
07/25/2025 12:08:49

reported-sunday-allogene-reports-31-confirmed-response-rate-with-allo-316-in-cd70-high-rcc-patients-at-asco-with-durable-remissions-and-manageable-safety
Reported Sunday, Allogene Reports 31% Conf...
06/02/2025 06:57:54

Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Me...

allogene-therapeutics-reveals-asco-2025-abstracts-featuring-allo-316-oral-presentation-in-kidney-cancer-and-cema-cel-alpha3-tip-poster
Allogene Therapeutics Reveals ASCO 2025 Ab...
05/22/2025 21:28:30

citigroup-maintains-buy-on-allogene-therapeutics-lowers-price-target-to-4
Citigroup Maintains Buy on Allogene Therap...
05/15/2025 14:37:18

Citigroup analyst Samantha Semenkow maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target fro...

truist-securities-maintains-buy-on-allogene-therapeutics-lowers-price-target-to-10
Truist Securities Maintains Buy on Allogen...
05/14/2025 16:07:38

Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price...

piper-sandler-maintains-overweight-on-allogene-therapeutics-lowers-price-target-to-7
Piper Sandler Maintains Overweight on Allo...
05/14/2025 16:04:34

Piper Sandler analyst Biren Amin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Overweight and lowers the price target...

rbc-capital-reiterates-outperform-on-allogene-therapeutics-maintains-10-price-target
RBC Capital Reiterates Outperform on Allog...
05/14/2025 15:08:05

RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and maintains $10 price target.

oppenheimer-maintains-outperform-on-allogene-therapeutics-lowers-price-target-to-9
Oppenheimer Maintains Outperform on Alloge...
05/14/2025 14:29:42

Oppenheimer analyst Matthew Biegler maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price tar...

baird-maintains-outperform-on-allogene-therapeutics-lowers-price-target-to-9
Baird Maintains Outperform on Allogene The...
05/14/2025 13:12:58

Baird analyst Jack Allen maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price target from $...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION